The abstract "PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy" has been selected by the ASH Program Committee for presentation in an Oral Session at the 59th Annual Meeting and Exposition (December 9-12, 2017) in Atlanta, GA.
Session Name: 632: Chronic Myeloid Leukemia: Therapy: Results of Clinical Trials
Session Date: December 11, 2017
Publication Number: 895
Submission ID: 104013
In addition to the presentation, the abstract will also be published online in the December 8 supplemental volume of Blood.
The world's most comprehensive hematology event of the year, the 59th ASH Annual Meeting and Exposition. The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.